Pathos AI Inc., a biotechnology company focused on improving precision medicine in cancer by harnessing the power of machine learning to transform drug development, has announced the world-wide license of PRT811, a potent, selective, and orally bioavailable brain penetrant SAM-competitive PRMT5 inhibitor from Prelude Therapeutics.   PRT811 (renamed P-500) was developed by Prelude Therapeutics and completed a Phase 1 trial in March 2023. Results from Prelude’s Phase 1 Study The trial enrol...